Pharmaceutical Technology1 天
NUC-7738 by NuCana for Lung Adenocarcinoma: Likelihood of Approval
NUC-7738 is under clinical development by NuCana and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II drugs for Lung Adenocarcinoma does not have sufficient historical ...
Pharmaceutical Technology1 天
Erdafitinib by Johnson & Johnson for Lung Adenocarcinoma: Likelihood of Approval
Erdafitinib is under clinical development by Johnson & Johnson and currently in Phase I for Lung Adenocarcinoma.
Cure Today4 天
Subcutaneous Opdivo Receives FDA Approval for Advanced, Metastatic Solid Tumors
Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...
Targeted Oncology4 天
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
Study unravels the earliest cellular genesis of lung adenocarcinoma
uncovering new cellular pathways and precursors in the development of lung adenocarcinoma, the most common type of lung ...
Managed Healthcare Executive3 天
FDA Approves Subcutaneous Opdivo to Treat Solid Tumors
Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...
Medscape3 天
An Update on the Evaluation and Management of Small Pulmonary Nodules
The widespread utilization of chest CT scans has increased the importance of the proper evaluation of incidentally found lung nodules ... or partially solid nodules may require longer follow ...
The Pharma Letter4 天
FDA approves new injectable version of Opdivo
The US Food and Drug Administration (FDA) on Friday approved nivolumab and hyaluronidase-nvhy, under the trade name Opdivo ...
FDA approves Bristol Myers’ Opdivo Qvantig
The Food and Drug Administration announced it has approved nivolumab and hyaluronidase-nvhy, Opdivo Qvantig, from Bristol Myers (BMY) Squibb, ...